Gastric antral vascular ectasia (GAVE) in early diffuse SSc: Report from the SCOT trial
K. Sullivan(University of Michigan), Mayes, Lynette Keyes-Elstein(National Institute of Allergy and Infectious Diseases), D. H. Wallace, Peter A. McSweeney(Mesoblast (United States)), LJ Crofford, D.E. Furst(University of California, Los Angeles), ME Csuka, Ellen Goldmuntz(National Institute of Allergy and Infectious Diseases), R Nash
Arthritis & Rheumatism
August 31, 2008
Cited by 4
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k